Medical Developments International Limited · ASX:MVP
Medical Developments International — Non-Deal Roadshow (March 2021)
10 slides from Medical Developments International's roadshow presentation, Mar 8, 2021
Slide 1: MVP Roadshow Presentation
MVP Roadshow Presentation March 2021
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other
Slide 3: Current Results are Challenging but we are Investing for the Future
Current Results are Challenging but we are Investing for the Future • H1 FY21 results adversely affected by COVID-19 • Respiratory sales lower, due to: - Milder cold and flu season - lowering asthma-related demand; - COVID-19 inspired surge buying late in FY20. • Penthrox sales lower, due to: - sell
Slide 4: Our H1 FY21 Financial Performance
Our H1 FY21 Financial Performance • Overall gross revenue grew 14% over H1 FY20 … • … but much of this growth is from contract income • Respiratory sales lower – COVID-19 impact • Modest growth in our international Penthrox business despite COVID-19 impact • Gross Margins remain strong • Successful
Slide 5: Penthrox is Growing in Europe
Penthrox is Growing in Europe Units 3 month moving average 14,000 • Hand back of the EU distribution rights (27 countries) from Mundipharma 12,000 • Booking of sales in our own right from March 10,000 1st post the 6-month transition process 8,000 • Sales growing despite a 60-70% decrease in 6,000 em
Slide 6: Our Current 'Hybrid' Model
Our Current ‘Hybrid’ Model MVP GALEN ⚫ France ⚫ UK and Ireland ⚫ Italy ⚫ Nordic region: ⚫ Spain - Sweden, Norway, ⚫ Germany Finland, Denmark ⚫ Belgium and Iceland ⚫ The Netherlands ⚫ Luxembourg In Negotiation ⚫ Switzerland ⚫ Poland Future ⚫ Portugal ⚫ Greece ⚫ Romania ⚫ Bulgaria MEDIS ⚫ Baltic State
Slide 7: France is operational; Germany, Spain and Italy plans are underway
France is operational; Germany, Spain and Italy plans are underway France • First Key Account Manager (KAM) began in February • Additional KAM’s to follow before end of FY21 Germany • 250 local ambulance services • A team of KAM’s are due to begin in mid-2021 Spain • A mix of hospital-funded and pri
Slide 8: Our Core Market Priorities in the Second Half
Our Core Market Priorities in the Second Half Penthrox – Australia Increased resourcing to support direct control of Penthrox distribution: • Marketing Manager, Key Account Managers with primary focus on hospitals in Victoria and NSW Key Initiatives: • Protocol development in hospitals where Penthro
Slide 9: We Continue to Pursue Longer term Opportunities
We Continue to Pursue Longer term Opportunities Penthrox in the US • Positive exchange with FDA Type-C meeting on January 21 • Awaiting final ‘post-meeting note’ regarding path forward Penthrox in China • Phase I Pharmaco-Kinetic (PK) study protocol finalised; first patient to be enrolled in Q3 2021
Slide 10: Medical Developments International
Medical Developments International
Medical Developments International — Non-Deal Roadshow (March 2021) on 6ix